Products
Siplizumab Biosimilar Monoclonal Antibody (CD2) for Research
Cat No.: GMP-Bios-INN-992
Anti-CD2 therapeutic antibody (Pre-made Siplizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Siplizumab (MEDI-57) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.[1]
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-992-1mg | 1mg | 3090 |
| GMP-Bios-INN-992-10mg | 10mg | |
| GMP-Bios-INN-992-100mg | 100mg | |
| GMP-Bios-INN-992-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Siplizumab Biosimilar, Whole Mab, Anti-Cd2 Antibody: Anti-LFA-2/SRBC/T11 therapeutic antibody |
| INN Name | Siplizumab |
| Target | CD2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | BioTransplant (Charlestown MA USA) / MedImmune (Gaithersburg MD USA) / AstraZeneca (London UK) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
